Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Autor: Schiffer CA; Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children's National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel, Patient Representative, Grand Island, NE; John M. Rainey, University Health Center, Lafayette, LA; Paolo Rebulla, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Scott D. Rowley, Hackensack University Medical Center, Hackensack, NJ; Michael B. Troner, Miami Cancer Institute, Miami, FL; and Kenneth C. Anderson, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Bohlke K; Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children's National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel, Patient Representative, Grand Island, NE; John M. Rainey, University Health Center, Lafayette, LA; Paolo Rebulla, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Scott D. Rowley, Hackensack University Medical Center, Hackensack, NJ; Michael B. Troner, Miami Cancer Institute, Miami, FL; and Kenneth C. Anderson, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Delaney M; Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children's National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel, Patient Representative, Grand Island, NE; John M. Rainey, University Health Center, Lafayette, LA; Paolo Rebulla, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Scott D. Rowley, Hackensack University Medical Center, Hackensack, NJ; Michael B. Troner, Miami Cancer Institute, Miami, FL; and Kenneth C. Anderson, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Hume H; Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children's National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel, Patient Representative, Grand Island, NE; John M. Rainey, University Health Center, Lafayette, LA; Paolo Rebulla, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Scott D. Rowley, Hackensack University Medical Center, Hackensack, NJ; Michael B. Troner, Miami Cancer Institute, Miami, FL; and Kenneth C. Anderson, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Magdalinski AJ; Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children's National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel, Patient Representative, Grand Island, NE; John M. Rainey, University Health Center, Lafayette, LA; Paolo Rebulla, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Scott D. Rowley, Hackensack University Medical Center, Hackensack, NJ; Michael B. Troner, Miami Cancer Institute, Miami, FL; and Kenneth C. Anderson, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., McCullough JJ; Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children's National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel, Patient Representative, Grand Island, NE; John M. Rainey, University Health Center, Lafayette, LA; Paolo Rebulla, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Scott D. Rowley, Hackensack University Medical Center, Hackensack, NJ; Michael B. Troner, Miami Cancer Institute, Miami, FL; and Kenneth C. Anderson, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Omel JL; Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children's National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel, Patient Representative, Grand Island, NE; John M. Rainey, University Health Center, Lafayette, LA; Paolo Rebulla, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Scott D. Rowley, Hackensack University Medical Center, Hackensack, NJ; Michael B. Troner, Miami Cancer Institute, Miami, FL; and Kenneth C. Anderson, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Rainey JM; Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children's National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel, Patient Representative, Grand Island, NE; John M. Rainey, University Health Center, Lafayette, LA; Paolo Rebulla, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Scott D. Rowley, Hackensack University Medical Center, Hackensack, NJ; Michael B. Troner, Miami Cancer Institute, Miami, FL; and Kenneth C. Anderson, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Rebulla P; Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children's National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel, Patient Representative, Grand Island, NE; John M. Rainey, University Health Center, Lafayette, LA; Paolo Rebulla, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Scott D. Rowley, Hackensack University Medical Center, Hackensack, NJ; Michael B. Troner, Miami Cancer Institute, Miami, FL; and Kenneth C. Anderson, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Rowley SD; Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children's National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel, Patient Representative, Grand Island, NE; John M. Rainey, University Health Center, Lafayette, LA; Paolo Rebulla, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Scott D. Rowley, Hackensack University Medical Center, Hackensack, NJ; Michael B. Troner, Miami Cancer Institute, Miami, FL; and Kenneth C. Anderson, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Troner MB; Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children's National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel, Patient Representative, Grand Island, NE; John M. Rainey, University Health Center, Lafayette, LA; Paolo Rebulla, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Scott D. Rowley, Hackensack University Medical Center, Hackensack, NJ; Michael B. Troner, Miami Cancer Institute, Miami, FL; and Kenneth C. Anderson, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Anderson KC; Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children's National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel, Patient Representative, Grand Island, NE; John M. Rainey, University Health Center, Lafayette, LA; Paolo Rebulla, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Scott D. Rowley, Hackensack University Medical Center, Hackensack, NJ; Michael B. Troner, Miami Cancer Institute, Miami, FL; and Kenneth C. Anderson, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Jazyk: angličtina
Zdroj: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2018 Jan 20; Vol. 36 (3), pp. 283-299. Date of Electronic Publication: 2017 Nov 28.
DOI: 10.1200/JCO.2017.76.1734
Abstrakt: Purpose To provide evidence-based guidance on the use of platelet transfusion in people with cancer. This guideline updates and replaces the previous ASCO platelet transfusion guideline published initially in 2001. Methods ASCO convened an Expert Panel and conducted a systematic review of the medical literature published from September 1, 2014, through October 26, 2016. This review builds on two 2015 systematic reviews that were conducted by the AABB and the International Collaboration for Transfusion Medicine Guidelines. For clinical questions that were not addressed by the AABB and the International Collaboration for Transfusion Medicine Guidelines (the use of leukoreduction and platelet transfusion in solid tumors or chronic, stable severe thrombocytopenia) or that were addressed partially (invasive procedures), the ASCO search extended back to January 2000. Results The updated ASCO review included 24 more recent publications: three clinical practice guidelines, eight systematic reviews, and 13 observational studies. Recommendations The most substantial change to a previous recommendation involved platelet transfusion in the setting of hematopoietic stem-cell transplantation. Based on data from randomized controlled trials, adult patients who undergo autologous stem-cell transplantation at experienced centers may receive a platelet transfusion at the first sign of bleeding, rather than prophylactically. Prophylactic platelet transfusion at defined platelet count thresholds is still recommended for pediatric patients undergoing autologous stem-cell transplantation and for adult and pediatric patients undergoing allogeneic stem-cell transplantation. Other recommendations address platelet transfusion in patients with hematologic malignancies or solid tumors or in those who undergo invasive procedures. Guidance is also provided regarding the production of platelet products, prevention of Rh alloimmunization, and management of refractoriness to platelet transfusion ( www.asco.org/supportive-care-guidelines and www.asco.org/guidelineswiki ).
Databáze: MEDLINE